Gryphon: People make proteins
Cells are good at making proteins, people are not. Biotechnology started with proteins, but in the past few years, much of the industry's emphasis has shifted to small molecules, based on their advantages in oral delivery and low cost manufacturing. The genomics revolution may shift the pendulum once again, as the discovery of a multitude of novel proteins, about which little is known, focuses attention back on these large molecules.
Gryphon Sciences is positioning itself to take advantage of this shift with technology for the total chemical synthesis of proteins and protein-like molecules called Dextroceutical and Nanoceutical products.
There are two main challenges in protein chemistry: the synthesis of pure quantities of large